Travere Therapeutics Announces Plan for Chief Financial Officer Transition
April 20, 2022 16:30 ET
|
Travere Therapeutics, Inc.
Laura Clague to step-down as CFO in August 2022 and retire in 2023 Chris Cline, Travere SVP of Investor Relations & Corporate Communications, to assume position of chief financial officer in...
Travere Therapeutics Provides Corporate Update and 2022 Outlook
January 10, 2022 07:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for...
Travere Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
November 30, 2020 16:05 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating...